If you rely on lower-cost compounded GLP-1 injections, plan now with your physician for a transition to an approved product, and be sure to avoid unapproved products or those marketed for research purposes. Will my insurance pay for name-brand GLP-1s
These issues are usually accompanied by obesity and might add some risks of other serious health concerns such as heart disease, stroke, and kidney disease
Because GHK-Cu is studied as a naturally declining protective factor, with research examining its roles in maintaining extracellular matrix integrity, protecting against oxidative stress, and supporting tissue repair capacity, it is a central subject in experiments related to age-related tissue changeswithout implying outcomes outside of a research setting.

Several GLP-1 agonists have FDA approval for other indications that may overlap with BED patient populations: Semaglutide (Wegovy) and liraglutide (Saxenda) are approved for chronic weight management in adults with obesity (BMI 30) or overweight (BMI 27) with at least one weight-related comorbidity Semaglutide (Ozempic), liraglutide (Victoza), dulaglutide (Trulicity), and tirzepatide (Mounjaro) are approved for type 2 diabetes management Tirzepatide (Zepbound) is approved for chronic weight management When clinicians prescribe GLP-1 agonists for BED, this constitutes off-label use a legal and common practice in medicine when evidence suggests potential benefit and approved treatments are inadequate